412 related articles for article (PubMed ID: 23262034)
1. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q; Lozano G
Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
[TBL] [Abstract][Full Text] [Related]
2. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
3. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.
Vogel SM; Bauer MR; Joerger AC; Wilcken R; Brandt T; Veprintsev DB; Rutherford TJ; Fersht AR; Boeckler FM
Proc Natl Acad Sci U S A; 2012 Oct; 109(42):16906-10. PubMed ID: 23035244
[TBL] [Abstract][Full Text] [Related]
4. Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.
Teveroni E; Lucà R; Pellegrino M; Ciolli G; Pontecorvi A; Moretti F
Expert Opin Ther Pat; 2016 Dec; 26(12):1417-1429. PubMed ID: 27603098
[TBL] [Abstract][Full Text] [Related]
5. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
6. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
7. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
8. Targeting p53 for the treatment of cancer.
Duffy MJ; Synnott NC; O'Grady S; Crown J
Semin Cancer Biol; 2022 Feb; 79():58-67. PubMed ID: 32741700
[TBL] [Abstract][Full Text] [Related]
9. Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.
Espadinha M; Lopes EA; Marques V; Amaral JD; Dos Santos DJVA; Mori M; Daniele S; Piccarducci R; Zappelli E; Martini C; Rodrigues CMP; Santos MMM
Eur J Med Chem; 2022 Nov; 241():114637. PubMed ID: 35961068
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
11. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
[TBL] [Abstract][Full Text] [Related]
13. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of p53: from peptides to small molecules.
Brown CJ; Cheok CF; Verma CS; Lane DP
Trends Pharmacol Sci; 2011 Jan; 32(1):53-62. PubMed ID: 21145600
[TBL] [Abstract][Full Text] [Related]
15. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
16. Peptide activators of the p53 tumor suppressor.
Zhan C; Lu W
Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
[TBL] [Abstract][Full Text] [Related]
17. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
18. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
19. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
Toledo F; Wahl GM
Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Shangary S; Wang S
Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
